NRX Pharmaceuticals Return on Equity

NRX Pharmaceuticals (NRXP) currently reports a ROE of 13811.76%. That is above the Healthcare sector average of 20.86%. Use the charts on this page to explore NRX Pharmaceuticals's ROE history and peer comparisons.

NRX Pharmaceuticals's ROE of 13811.76% is higher than the Healthcare sector average of 20.86%. That is roughly 66121.9% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but NRX Pharmaceuticals's current 13811.76% should be judged against Healthcare norms (sector average: 20.86%) and against NRXP's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 13811.76%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.86%. From there, open related valuation or income-statement pages for NRX Pharmaceuticals, and consider following NRXP for alerts when major investors trade the stock.

NRX Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows 13811.76% versus a sector average near 20.86%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NRXP with unrelated industries.